Century Therapeutics(US:IPSC)2026-03-12 12:04Financial Position - The company has cash, cash equivalents, and investments totaling $117.1 million as of December 31, 2025, with an additional $126.7 million raised from a private placement, expected to fund operations into Q1 2029 [555]. - Cash and cash equivalents stood at $61.9 million, with investments of $55.3 million as of December 31, 2025, providing sufficient liquidity to fund operations into Q1 2029 [595]. - As of December 31, 2025, the company had cash, cash equivalents, and restricted cash totaling $65 million, along with investments of $55.3 million [644]. Research and Development - The company is advancing its CNTY-813 beta islet program for T1D, with IND-enabling studies underway and an IND application anticipated as early as 2026 [551]. - CNTY-308, a CD19-targeted CAR-iT cell therapy, is also progressing towards clinical studies expected to start in 2026 following successful IND-enabling studies [552]. - The company plans to prioritize clinical development for CNTY-101, a CAR-iNK cell therapy, currently enrolling patients in a Phase 1/2 study [553]. - Research and development expenses have primarily focused on the iPSC cell therapy platform and product candidates, with significant increases anticipated in the future [576]. - Research and development expenses were $95.7 million in 2025, down from $107.2 million in 2024, reflecting a decrease of $11.6 million mainly due to reduced personnel costs [589]. - Research and development expenses are recorded as incurred, with clinical trial costs expensed based on estimates of work completed [632][635]. Revenue and Collaborations - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future, relying on future collaborations for revenue [575]. - Collaboration revenue increased significantly to $109.2 million in 2025 from $6.6 million in 2024, primarily due to the recognition of the remaining transaction price under the terminated Collaboration Agreement with Bristol-Myers Squibb [588]. - The company has entered into a collaboration agreement with Bristol-Myers Squibb, which included a $100 million upfront payment, but this agreement was terminated in March 2025 [559][561]. - The company has made payments of $2.0 million and incurred R&D expenses of $0.9 million related to its collaboration agreements with FCDI during the years ended December 31, 2025, and 2024 [567]. - Collaboration revenue may include non-refundable upfront fees, milestone payments, and royalties on product sales, recognized under ASC Topic 606 [623][624]. Operating Expenses - Total operating expenses decreased to $126.4 million in 2025 from $144.7 million in 2024, a reduction of $18.3 million [587]. - General and administrative expenses decreased to $24.0 million in 2025 from $33.2 million in 2024, a decline of $9.2 million attributed to lower legal fees and stock-based compensation [591]. - Impairment of long-lived assets was recorded at $6.8 million in 2025, compared to no impairment in 2024 [592]. Financial Performance - Net loss narrowed to $9.6 million in 2025 from $126.6 million in 2024, an improvement of $116.9 million [587]. - Net cash used in operating activities was $103.9 million in 2025, slightly improved from $110.1 million in 2024 [605]. - Net cash used in operating activities was $110.1 million for the year ended December 31, 2024, driven by a net loss of $126.6 million [608]. - Non-cash charges amounted to $25.7 million, primarily due to $13.3 million in depreciation, $12.7 million in stock-based compensation, and $4.3 million in goodwill impairment [608]. Future Financing - Future financing will be necessary to support operations, including preclinical studies and clinical trials, as the company does not expect to generate significant product revenue soon [558]. - The company anticipates needing additional financing in the future to support ongoing research and development efforts and potential commercialization of product candidates [601]. Market Risks and Assumptions - The primary exposure to market risk is interest income sensitivity, which is influenced by changes in U.S. interest rates; however, the low risk profile of the portfolio means changes in rates would not materially impact financial results [644]. - The company does not currently have material exposure to foreign currency fluctuations and does not engage in hedging activities [643]. - Inflation has increased costs related to labor and laboratory consumables, but it has not had a material effect on the financial statements [646]. - Significant assumptions in fair value estimation include projected revenues, regulatory approval probabilities, and market penetration [640]. - The estimation of fair value is sensitive to changes in key assumptions, particularly regarding regulatory approval and future cash flows [641]. - Adverse changes in clinical trial results or regulatory outcomes could lead to future impairment charges [642]. - The company maintains a qualitative assessment to evaluate the fair value of assets against their carrying amounts [640].